Bristol-Myers Squibb Company
Fibronectin based scaffold domain proteins that bind PCSK9

Last updated:

Abstract:

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Status:
Grant
Type:

Utility

Filling date:

21 Nov 2017

Issue date:

16 Mar 2021